Does Johnson & Johnson (NYSE:JNJ) Have A Healthy Balance Sheet?
A Quick Look at Today's Ratings for Johnson & Johnson(JNJ.US), With a Forecast Between $166 to $185
Goldman Sachs Lowers Price Target on Johnson & Johnson to $159 From $162
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
Johnson & Johnson's 'Better-Than-Expected Operational Execution' Drove Q3 Beat, RBC Says
Least Shorted S&P 500 Stocks in September
Johnson & Johnson Price Target Raised to $166.00/Share From $163.00 by Wells Fargo
A Quick Look at Today's Ratings for Johnson & Johnson(JNJ.US), With a Forecast Between $166 to $215
Johnson & Johnson Is Maintained at Outperform by RBC Capital
Express News | Morgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $175
Johnson & Johnson Analyst Ratings
Johnson & Johnson (JNJ) Receives a Buy From Cantor Fitzgerald
Bernstein Adjusts Price Target on Johnson & Johnson to $177 From $171, Maintains Market Perform Rating
Reported Earlier, Johnson & Johnson Ordered To Pay $15M In Connecticut Asbestos Case, Facing Potential For Punitive Damagesjnj
Express News | J&J : RBC Raises Target Price to $181 From $178
Hold Rating for Johnson & Johnson Amid 2024 Growth Deceleration and 2025 Optimism
Johnson & Johnson To Go Ex-Dividend On November 26th, 2024 With 1.24 USD Dividend Per Share
Express News | Johnson & Johnson Shares Rise 1.36% at $163.82
Express News | J&J's Talc Powder Is Responsible for Connecticut Man's Cancer, Jury Finds
Cancer Drugs Propel J&J Beyond Wall Street Estimates